Navigation Links
New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy
Date:6/13/2010

Previous data shows that a reduction in CHOP chemotherapy dose intensity below 90%(ii) may decrease survival in patients with aggressive NHL.

"These data confirm the significant impact febrile neutropenia can have on chemotherapy delivery in NHL, possibly reducing the favourable outcome of the treatment. There is a need for early prophylaxis with G-CSFs in those patients at risk," said Dr Ruth Pettengell, presenting author of the study and Senior Lecturer in Haematology and Honorary Consultant in Oncology at St George's Hospital Medical School, University of London.

Unplanned hospitalisations were also greater in patients who experienced FN (79% versus 18% in R-CHOP-21; 78% versus 21% in R-CHOP-14).

Based on these data from everyday clinical practice, the authors conclude physicians should implement guidelines on G-CSF use and G-CSF primary prophylaxis should be considered for NHL patients receiving R-CHOP-21 chemotherapy, who are assessed as having an overall FN risk of 20% or higher, and for all patients receiving R-CHOP-14.

Use of G-CSF primary phrophylaxis to prevent FN differed between the two groups; less than half of R-CHOP-21 patients (36%) were given G-CSF primary prophylaxis, compared to 84% of the R-CHOP-14 group and incidence of FN was 19% and 20% respectively.

About the Study

The aim of the IMPACT NHL study was to assess the impact of febrile neutropenia (FN) on non-Hodgkin lymphoma (NHL) patients receiving CHOP chemotherapy in combination with rituximab(R) every two (14 days) or three (21 days) weeks (current standard of care).

The study was supported by Amgen and included a total of 1,829 patients over the age of 18 with NHL receiving either R-CHOP-14 or R-
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Watson Confirms Renvela® Patent Challenge
2. China Sky One Medical Confirms Continued Sale of Seven of Eight Products on the Ministry of Healths Warning List
3. Publication in Neuropsychopharmacology Confirms CeNeRxs Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
4. Vivakor Confirms Record Date of Stock Dividend
5. New study confirms exotic electric properties of graphene
6. Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products
7. Analysis confirms that nano-related research has strong multidisciplinary roots
8. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
9. Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
10. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
11. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. George ... Society for Reproductive Medicine (ASRM), a leading professional organization ... In his new role as treasurer, Dr. Hill ... will have a voice in furthering the mission of ... since 1984 when he joined while conducting fellowship training ...
(Date:12/24/2014)... December 23, 2014 PharmaBoardroom,s ... out today and available for free download , digs ... change and growth in the sector today. One ... successes has been in developing a homegrown pharmaceutical manufacturing base, ... production still remains some way off. A cursory comparison with ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... DUBLIN, October 28 , ... EU to Treat,hyperphosphataemia >1.78mmol/L in Chronic Kidney Disease Patients ... (LSE: SHP, NASDAQ: SHPGY ), the global specialty,biopharmaceutical ... Mutual Recognition Procedure for an extension to the current,indication ...
... ... An incident of terrorism, accident, or improper disposal of radioactive ... catastrophe would impact the population with increased cancer and associated illnesses ... distribution network. In response to this threat, Technical Associates created the ...
... Oct. 27 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... authorization in the European Union for rilonacept, an ... Syndromes (CAPS) with severe symptoms, including Familial Cold ... adults and children aged 12 years and older. ...
Cached Biology Technology:Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease 2Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease 3Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease 4Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law 2Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law 3Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law 4Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) 2Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) 3Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) 4Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) 5Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) 6
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... 2013Universit Laval researchers have developed a highly effective method for ... low-emissions fuel for vehicles. The team led by Professor Frdric-Georges ... issue of the Journal of the American Chemical Society ... convert methanol into carbon dioxide in a single step using ...
... of genetically modified mice that Western University scientists call ... run far but they aren,t smart, is furthering the ... Marco Prado and his team at Robarts Research Institute ... of this neurotransmitter becomes available in the brain. ...
... 2013 Based on its recent analysis of the ... with the 2013 European Frost & Sullivan Award for ... originally used for medical point-of-care testing to create an ... test requires only a single-step DNA collection procedure from ...
Cached Biology News:Too green to be true? Researchers develop highly effective method for converting CO2 into methanol 2'Forrest Gump' mice show too much of a good thing, can be bad 2Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market 2Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market 3Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market 4
Rabbit polyclonal to ZA20D3 ( Abpromise for all tested applications). entrezGeneID: 54469 SwissProtID: Q6FIF0...
... Super-Dark, Super-Small! Capture high-resolution chemiluminescent ... Imaging System. High-sensitivity camera is cooled ... and wide dynamic range for high ... time. The light-tight cabinet provides optimum ...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Biology Products: